Accuracy of Japanese claims data in identifying diabetes-related complications.
claims-based diagnosis
complications
diabetes
pharmacoepidemiology
validity
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
26
01
2021
received:
25
11
2020
accepted:
22
02
2021
pubmed:
26
2
2021
medline:
25
11
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
To evaluate the accuracy of various claims-based definitions of diabetes-related complications (coronary artery disease [CAD], heart failure, cerebrovascular disease and dialysis). We evaluated data on 1379 inpatients who received care at the Niigata University Medical & Dental Hospital in September 2018. Manual electronic medical chart reviews were conducted for all patients with regard to diabetes-related complications and were used as the gold standard. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each claims-based definition associated with diabetes-related complications based on Diagnosis Procedure Combination (DPC), International Classification of Diseases, Tenth Revision (ICD-10) codes, procedure codes and medication codes were calculated. DPC-based definitions had higher sensitivity, specificity, and PPV than ICD-10 code definitions for CAD and cerebrovascular disease, with sensitivity of 0.963-1.000 and 0.905-0.952, specificity of 1.000 and 1.000, and PPV of 1.000 and 1.000, respectively. Sensitivity, specificity, and PPV were high using procedure codes for CAD and dialysis, with sensitivity of 0.963 and 1.000, specificity of 1.000 and 1.000, and PPV of 1.000 and 1.000, respectively. DPC and/or ICD-10 codes + medication were better for heart failure than the ICD-10 code definition, with sensitivity of 0.933, specificity of 1.000, and PPV of 1.000. The PPVs were lower than 60% for all diabetes-related complications using ICD-10 codes only. The DPC-based definitions for CAD and cerebrovascular disease, procedure codes for CAD and dialysis, and DPC or ICD-10 codes with medication codes for heart failure could accurately identify these diabetes-related complications from claims databases.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-601Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy. 2009;29(2):138-153.
Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open. 2019;2(10):e1912869.
Rumbold JMM, O'Kane M, Philip N, Pierscionek BK. Big data and diabetes: the applications of big data for diabetes care now and in the future. Diabet Med. 2020;37(2):187-193.
Wang SD. Opportunities and challenges of clinical research in the big-data era: from RCT to BCT. J Thorac Dis. 2013;5(6):721-723.
Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose Cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose Cotransporter-2 inhibitors). Circulation. 2017;136(3):249-259.
Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628-2639.
Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139(25):2822-2830.
Kaku K, Kisanuki K, Shibata M, Oohira T. Benefit-risk assessment of Alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf. 2019;42(11):1311-1327.
Yabe D, Hamamoto Y, Seino Y, Kuwata H, Kurose T, Seino Y. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opin Drug Saf. 2017;16(10):1211-1218.
Sugiyama T, Imai K, Ihana-Sugiyama N, et al. Variation in process quality measures of diabetes care by region and institution in Japan during 2015-2016: an observational study of nationwide claims data. Diabetes Res Clin Pract. 2019;155:107750.
Nishioka Y, Okada S, Noda T, et al. Absolute risk of acute coronary syndrome after severe hypoglycemia: a population-based 2-year cohort study using the National Database in Japan. J Diabetes Investig. 2020;11(2):426-434.
Kawasaki R, Konta T, Nishida K. Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database. Diabetes Obes Metab. 2018;20(10):2351-2360.
Fujihara K, Igarashi R, Yamamoto M, et al. Impact of glucose tolerance status on the development of coronary artery disease among working-age men. Diabetes Metab. 2017;43(6):543-546.
Fujihara K, Matsubayashi Y, Yamamoto M, et al. Impact of body mass index and metabolic phenotypes on coronary artery disease according to glucose tolerance status. Diabetes Metab. 2017;43(3):261-264.
Yamada-Harada M, Fujihara K, Osawa T, et al. Relationship between number of multiple risk factors and coronary artery disease risk with and without diabetes mellitus. J Clin Endocrinol Metab. 2019;104(11):5084-5090.
Kitazawa M, Fujihara K, Osawa T, et al. Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men. Metabolism. 2019;101:153991.
Health Insurance Claims Review & Reimbursement Services.Computerized processing system of claims. 2020. http://www.ssk.or.jp/rezept/index.html
Koram N, Delgado M, Stark JH, Setoguchi S, de Luise C. Validation studies of claims data in the Asia-Pacific region: a comprehensive review. Pharmacoepidemiol Drug Saf. 2019;28(2):156-170.
Iwagami M, Akazawa M, Ishiguro C, et al. Task force report on the validation of diagnosis codes and other outcome definitions in the Japanese receipt data. Jpn J Pharmacoepidemiol. 2018;23(2):95-146.
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
Hsieh CY, Su CC, Shao SC, et al. Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349-358.
McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS One. 2014;9(3):e92286.
Cozzolino F, Montedori A, Abraha I, et al. A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria data-value project. PLoS One. 2019;14(7):e0218919.
Presley CA, Min JY, Chipman J, et al. Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration. BMJ Open. 2018;8(3):e020455.
Bosco-Lévy P, Duret S, Picard F, et al. Diagnostic accuracy of the international classification of diseases, tenth revision, codes of heart failure in an administrative database. Pharmacoepidemiol Drug Saf. 2019;28(2):194-200.
Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236-242.
Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc. 2015;114(3):254-259.
Park TH, Choi JC. Validation of stroke and thrombolytic therapy in Korean National Health Insurance Claim Data. J Clin Neurol. 2016;12(1):42-48.
Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005;46(2):225-232.
Ronksley PE, Tonelli M, Quan H, et al. Validating a case definition for chronic kidney disease using administrative data. Nephrol Dial Transplant. 2012;27(5):1826-1831.
Bush M, Stürmer T, Stearns SC, et al. Position matters: validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study. Pharmacoepidemiol Drug Saf. 2018;27(10):1085-1091.
Grams ME, Plantinga LC, Hedgeman E, et al. Validation of CKD and related conditions in existing data sets: a systematic review. Am J Kidney Dis. 2011;57(1):44-54.
Campbell SE, Campbell MK, Grimshaw JM, Walker AE. A systematic review of discharge coding accuracy. J Public Health Med. 2001;23(3):205-211.
Nissen F, Quint JK, Morales DR, Douglas IJ. How to validate a diagnosis recorded in electronic health records. Breathe (Sheff). 2019;15(1):64-68.
Mbizvo GK, Bennett KH, Schnier C, Simpson CR, Duncan SE, Chin RFM. The accuracy of using administrative healthcare data to identify epilepsy cases: a systematic review of validation studies. Epilepsia. 2020;61(7):1319-1335.
Matsuda SIK, Kuwabara K, Fujimori K, Fushimi K. Development and use of the Japanese case-mix system. Eurohealth. 2008;14:25-30.
Matsuda S. Development of case mix based evaluation system in Japan. Jpn Hosp. 2016;35:35-44.
Cutrona SL, Toh S, Iyer A, et al. Validation of acute myocardial infarction in the Food and Drug Administration's mini-sentinel program. Pharmacoepidemiol Drug Saf. 2013;22(1):40-54.
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol. 2014;24(6):500-507.
Wei WQ, Teixeira PL, Mo H, Cronin RM, Warner JL, Denny JC. Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. J Am Med Inform Assoc. 2016;23(1):e20-e27.
Shima D, Ii Y, Higa S, et al. Validation of novel identification algorithms for major adverse cardiovascular events in a Japanese claims database. J Clin Hypertens (Greenwich). 2020. https://doi.org/10.1111/jch.14151.
Sato I, Yagata H, Ohashi Y. The accuracy of Japanese claims data in identifying breast cancer cases. Biol Pharm Bull. 2015;38(1):53-57.
Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27(10):476-482.
Ando T, Ooba N, Mochizuki M, et al. Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: a validation study at a single center. BMC Health Serv Res. 2018;18(1):895.
Ono Y, Taneda Y, Takeshima T, Iwasaki K, Yasui A. Validity of claims diagnosis codes for cardiovascular diseases in diabetes patients in Japanese administrative database. Clin Epidemiol. 2020;12:367-375.
Medical Information System Development Center [homepage on the Internet]. Standard disease name master for ICD-10. Japanese. http://www2.medis.or.jp/stdcd/byomei/index.html. Accessed November 1, 2020.
Vlasschaert ME, Bejaimal SA, Hackam DG, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis. 2011;57(1):29-43.